Covidien, Massimo Extend Royalty Deal for Three Years

Medical device and drug maker Covidien PLC said Monday it extended a royalty agreement with medical technology company Masimo Corp. for its pulse oximetry products — devices that monitor oxygen in the bloodstream — sold in the United States.
Bloomberg